#4-71E. Delabeling with Confidence: The True Risk of Beta-Lactam Resensitization (JACIP, 2026)

Is it truly safe to re-administer beta-lactams after a patient has been successfully delabeled for a drug allergy? Today, we explore a systematic review and meta-analysis investigating the resensitization risk of beta-lactams following a negative initial standard evaluation. This comprehensive study analyzed 32 trials encompassing over 5,700 retests, revealing that the overall resensitization rate is remarkably low. Specifically, in robust drug provocation test-based studies, the resensitization rate was merely 2.44%, with severe reactions occurring in only 0.32% of cases. The pivotal clinical takeaway is that the observed resensitization risk is essentially equivalent to the natural incidence of de novo sensitizations in the general population, strongly indicating that routine retesting offers limited added benefit. However, when critically appraising this evidence, clinicians must note the substantial methodological heterogeneity across the included studies and recognize that patients with a prior history of anaphylaxis might harbor a higher resensitization risk, though current data remains limited. For practicing physicians, this paper is highly significant because it confidently supports the cessation of routine allergy retesting for most delabeled patients, reducing unnecessary medical burdens and safely promoting optimal first-line beta-lactam therapies in daily practice.

Citation: Srisuwatchari W, Sompornrattanaphan M. Resensitization of β-Lactams After Negative Initial Standard Evaluation: A Systematic Review and Meta-Analysis. The Journal of Allergy and Clinical Immunology: In Practice. 2026. DOI: https://doi.org/10.1016/j.jaip.2026.02.012

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.